MetaCap

Canton Strategic (CNTN) vs NRX Pharmaceuticals (NRXP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NRX Pharmaceuticals (NRXP) has outperformed Canton Strategic (CNTN) over the past year, gaining 0.9% versus a loss of 50.6%. Canton Strategic is the larger company by market cap ($98.8 million vs $95.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTN-50.61%NRXP+0.94%
+132%+37%-59%
Nov 21, 20251 yearNov 20, 2026
CNTN-99.89%NRXP-95.07%
+49%-29%-107%
Jan 10, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTN versus NRXP key metrics
MetricCNTNNRXP
Share price$1.21$2.15
Market cap$98.78M$95.31M
1-day change-1.63%-15.69%
YTD return-60.07%-20.66%
1-year return-50.61%+0.94%
5-year return—-96.81%
P/E ratio (TTM)20.17—
EPS (TTM)$0.06$-0.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.23M
Net income (latest FY)$-35.92M$-28.62M
Gross margin—58.78%
Operating margin—-1324.41%
Net margin—-2336.49%
52-week high$5.83$5.06
52-week low$1.19$1.62
Distance from 52-week high-79.25%-57.47%
Analyst consensus—strong_buy
Avg. price target upside—+1702.33%
Average volume763.63K1.07M
Shares outstanding81.64M44.33M
Employees1229
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NRXP has outperformed CNTN by 51.6 percentage points over the past year.

About Canton Strategic

CNTN stock →

Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About NRX Pharmaceuticals

NRXP stock →

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

CNTN vs NRXP FAQ

Which is bigger, Canton Strategic or NRX Pharmaceuticals?

Canton Strategic (CNTN) is larger, with a market capitalization of $98.78M compared with $95.31M for NRX Pharmaceuticals (NRXP).

Which stock has performed better over the past year, CNTN or NRXP?

NRXP returned +0.94% over the past 12 months, compared with -50.61% for CNTN (price return, excluding dividends). Past performance does not predict future results.

Are Canton Strategic and NRX Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons